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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV) comprises a group of systemic necrotising vascu-
litides, that often involve small vessels, and lead to few or no 
immune deposits in affected organs.1 AAV is classified into three 
variants such as microscopic polyangiitis (MPA), granulomato-
sis with polyangiitis (GPA), or eosinophilic GPA (EGPA) in ac-
cordance with clinical manifestations and histological features.2 
Of the three variants of AAV, EGPA, which is identical to what 
has been called Churg-Strauss syndrome, exhibits both allergic 
and vasculitis features. EGPA was first described as a syndrome 
consisting of asthma, fever, eosinophilia, and organ involve-
ment, including heart failure, neuropathy, and kidney damage, 
by Churg and Strauss in 1951.3 On the basis of the 2012 Chapel 
Hill Consensus Conferences Nomenclature of Vasculitis (the 
2012 CHCC definitions), EGPA has been characterised as hav-
ing three typical allergic components, including asthma, periph-
eral eosinophilia, and eosinophil-rich granuloma of the respi-
ratory tracts.1 EGPA has three clinical and histological stages: 
The first is an allergic stage composed of asthma and sinusitis. 
The second is an eosinophilic stage characterised by peripher-
al hypereosinophilia and intra-organ infiltration of eosino-
phils. The last is a vasculitic stage including necrotising inflam-
mation of small vessels and end-organ damages.4 For these 
reasons, in clinical settings, it can occasionally be confusing to 
distinguish EGPA from other allergic diseases and to select 
therapeutic regimens. In this review, we describe classification 
criteria and recommendations for the management of EGPA 
as well as currently used or attempted therapeutic regimens 
for EGPA. Also, we outline the results of recent studies on EGPA 
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in Korean patients. 
CLASSIFICATION CRITERIA AND 
DEFINITIONS
First, we should clarify our use of the term “definition of disease,” 
“classification criteria,” and “diagnostic criteria.” Definition of 
disease means abnormalities in a patient that warrant assign-
ment of a diagnostic term (name of disease), such as eosino-
phil-rich granuloma of the respiratory tract based on small-ves-
sel necrotising vasculitis compatible with EGPA. Classification 
criteria are observations that classify a patient into a stan-
dardised category for study, such as four or more of the follow-
ing six items for EGPA. Meanwhile, diagnostic criteria are an 
observation that demonstrates or confidently predicts the pres-
ence of the defining features of a disease in a patient.1,5 Since 
1951, when EGPA was first reported by Churg and Strauss, there 
have been several definitions and classification criteria for 
EGPA, and to date, there are no established definitive diagnos-
tic criteria for EGPA. 
In 1990, the first classification criteria for Churg-Strauss syn-
drome (or EGPA) were proposed by the American College of 
Rheumatology (the 1990 ACR criteria). The 1990 ACR criteria 
include the following six items: 1) asthma, 2) paranasal sinus 
abnormality, 3) peripheral blood eosinophilia (>10%), 4) un-
fixed pulmonary infiltration, 5) mononeuropathy or polyneu-
ropathy, and 6) extravascular eosinophils on histology. When 
four or more items are satisfied, a patient can firmly be classi-
fied as EGPA. The sensitivity and specificity of the 1990 ACR cri-
teria for EGPA have been reported as 85% and 99.7%.6 Due to 
their high specificity, the 1990 ACR criteria for EGPA have been 
most widely used to date. 
In 1994, the nomenclature of systemic vasculitis was pro-
posed by CHCC (the 1994 CHCC definitions). The 1994 CHCC 
definitions first provided standardised nomenclature of vas-
culitides and subgroups using generally and widely used ter-
minology. The 1994 CHCC definitions described EGPA as ex-
hibiting eosinophil-rich and granulomatous inflammation 
involving the respiratory tract and necrotizing vasculitis affect-
ing small to medium-sized vessels in association with asthma 
and eosinophilia.5
In 2007, a new algorithm for the classification of AAV and 
polyarteritis nodosa (PAN) was proposed by the European Medi-
cine Agency (the 2007 EMA algorithm).
The first requirement is a follow-up duration for 3 months or 
greater. The second requirement is an age of onset over 16 
years. The third requirement should meet all three of the fol-
lowing: 1) symptoms and signs compatible with AAV or PAN; 
2) at least one of i) histological evidence of vasculitis, ii) ANCA 
positivity, iii) specific investigations strongly suggestive of vas-
culitis or granuloma, or iv) eosinophilia (>10% or >1.5×109/L); 
and 3) no other diagnosis to account for symptoms and signs. 
When all three entry requirements are satisfied, the algorithm 
may be started. The first step of the 2007 EMA algorithm is to 
apply the 1990 ACR criteria for Churg-Strauss syndrome 
(EGPA) to a patient.7 As mentioned above, their high specifici-
ty enabled the 1990 ACR criteria for EGPA to be located on the 
top of the 2007 EMA algorithm. When a patient meets the 1990 
ACR criteria for EGPA, the remaining steps, including GPA, 
MPA and classic PAN, are not applied any more.
In 2012, the revised nomenclature of systemic vasculitides 
was proposed by CHCC (the 2012 CHCC definitions). These 
definitions divided small vessel vasculitis into two groups in-
cluding AAV and immune complex small vessel vasculitis. 
Thus, the 2012 definitions mentioned ANCA in the definitions 
of small vessel vasculitis for the first time. In addition, the 2012 
CHCC definitions encouraged to use of myeoloperoxidase 
(MPO)-ANCA, proteinase 3 (PR3)-ANCA, and ANCA-negative 
as prefixes. Compared to the 1994 CHCC definitions, the 2012 
CHCC definitions added three words (italicized text) as follow: 
EGPA is described as eosinophil-rich and necrotizing granulo-
matous inflammation often involving the respiratory tract, and 
necrotizing vasculitis predominantly affecting small to medium 
vessels in association with asthma and eosinophilia. This defini-
tion for EGPA emphasised concurrently existing necrosis and 
granulomatosis and suggested the frequencies of occurrence.1
In 2017, the ACR/European League Against Rheumatism 
(EULAR) provisional classification criteria for GPA was pro-
posed by a group of Diagnostic and Classification Criteria for 
Primary Systemic Vasculitis (DCVAS) and collaborators (pre-
sented at 2016 ACR session: New Classification Criteria for AN-
CA-associated Vasculitis: implications for clinical practice). 
These criteria consist of nine items and a total score of 5 or greater 
enables patients to be classified as GPA. Different scores are at-
tributed to each item: the highest score of 5 is assigned to PR3-
ANCA or C-ANCA positivity. In contrast, negative scores are 
allocated to nasal polyp and peripheral blood eosinophilia ≥1 
(×109/L) because both are clinical features favouring EGPA over 
GPA.8 These criteria were initially developed to classify patients 
as GPA: however, they may be useful to distinguish GPA and 
EGPA. For instance, when a patient exhibits bloody nasal dis-
charge (1), nasal polyp (-4), peripheral eosinophilia (-3), pain-
ful eye (1) and PR3-ANCA (5), the total score becomes 0. There-
fore, GPA can be excluded by the ACR/EULAR 2017 provisional 
classification criteria for GPA in this patient. We suggest that 
the ACR/EULAR 2017 provisional criteria can be useful to ex-
clude EGPA from GPA. However, these criteria should be ap-
plied next to the 2007 EMA algorithm and the 2012 CHCC 
definitions, as they are not fully validated and published.
RECOMMENDATIONS FOR 
MANAGEMENT OF AAV
In 2009, the EULAR recommendations for the management of 
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primary small and medium vessel vasculitis were published. 
An expert group consisting of 17 experts from eight European 
countries and the United States made 15 recommendations.9 
These recommendations have been made for the evaluation, 
investigation, treatment and monitoring of patients with small 
and medium vessel vasculitis for use in daily clinical practice 
based on evidence and expert consensus. However, the strength 
of the EULAR recommendations was reduced due to the low 
quality of evidence and by EULAR standardised operating pro-
cedure.
In 2015, an international task force representing EULAR and 
the European Renal Association–European Dialysis and Trans-
plant Association (ERA-EDTA) developed the 2015 updated 
recommendations for the management of AAV. These new rec-
ommendations were based on 1691 papers including licensing 
of rituximab for AAV in the past 5 years. The 2015 EULAR/ERA-
EDTA recommendation statements are modified and de-
scribed.10 
Among cases of organs or life-threatening AAV, plasma ex-
change should be considered in patients with rapidly progres-
sive renal failure [serum creatinine >500 μmol/L (5.7 mg/dL)] 
or diffuse alveolar haemorrhage. Otherwise, a combination of 
cyclophosphamide or rituximab with glucocorticoid should be 
administered. In cases of non-organ threatening AAV, a combi-
nation of methotrexate or mycophenolate mofetil with gluco-
corticoid is recommended. When remission is achieved, aza-
thioprine or methotrexate or rituximab are recommended as 
maintenance therapy and glucocorticoid should be continuously 
tapered. A combination of cyclophosphamide or rituximab 
with glucocorticoid should be started in patients with organ or 
life-threatening relapse. In patients with non-organ threatening 
relapse, a higher dose of glucocorticoid (intensification) and an 
alternative regimen (modification) are recommended. After 2 
years from the initiation of treatment, azathioprine or metho-
trexate should be tapered and rituximab should be stopped if 
possible.10 
RECOMMENDATIONS FOR EVALUATION 
AND MANAGEMT OF EGPA
The EGPA Consensus Task Force of experts from five European 
countries and the United States developed and provided the 22 
EGPA-specific recommendations for the evaluation and man-
agement of EGPA. The recommendations are modified and 
summarised. Among recommendations, the use of glucocorti-
coids for achieving remission of EGPA was ranked on a level of 
evidence of A. In addition, two recommendations were ranked 
at a level of B. A combination of glucocorticoid with an immu-
nosuppressant should be administered to patients with life-
threatening EGPA and leukotriene-receptor antagonist can be 
used to patients with EGPA. Unexpectedly, plasma exchange 
was not recommended to ANCA positive EGPA patients with 
rapidly progressive glomerulonephritis or pulmonary–renal 
syndrome as strongly as MPA or GPA patients with those mani-
festations (level of evidence of D). Use of rituximab was also 
limited for ANCA-positive patients with renal involvement or 
refractory disease at level of evidence of C. These recommen-
dations are important in that they focus on only EGPA patients 
not AAV.11 The future updated version of recommendations 
will be expected to emphasise rituximab use and describe anti-
interleukin (IL)-5 and anti-IL-5 receptor monoclonal antibod-
ies, such as mepolizumab, reslizumab and benralizumab. 
CONVENTIONAL AND BIOLOGICAL 
DRUGS FOR EGPA
So far there have been various clinical trials investigating new 
drugs as induction and maintain therapies beyond traditional 
immunosuppressive drugs such as cyclophosphamide and 
azathioprine in AAV patients. Among them, rituximab in AN-
CA-associated vasculitis (RAVE) and rituximab versus cyclo-
phosphamide in ANCA-associated vasculitis (RITUXVAS) trials 
demonstrated that rituximab is not inferior to cyclophospha-
mide as an induction therapy and contributed to the approval 
of rituximab as a first-line treatment in newly diagnosed pa-
tients with severe AAV.12,13 Cartin-Ceba, et al.14 reported that 
rituximab was effective and safe for the induction and mainte-
nance of remission in patients with refractory AAV. The mainte-
nance of remission using rituximab in systemic ANCA-associ-
ated vasculitis (MAINRITSAN) 1 trial investigated the efficacy 
of rituximab as a maintenance therapy in newly diagnosed AAV 
patients. They compared the therapeutic potentials between 
rituximab (infusion, 500 mg every 6 months for 18 months) and 
azathioprine (oral 2 mg/kg/day until 22 months) after the in-
duction therapy of cyclophosphamide, and demonstrated that 
rituximab was superior to azathioprine in maintenance therapy 
at 28 months.15 Moreover, there are several more ongoing clini-
cal trials for maintaining remission such as the RITAZAREM 
trial (rituximab versus azathioprine), the MAINTANCAVAS trial 
(rituximab), the REMAIN trial (extended period of azathioprine), 
and the MAINRITSAN trial (rituximab versus placebo).16 How-
ever, these clinical trials have included only MPA and GPA pa-
tients and occasionally renal-limited AAV patients. Until most 
recently, there have been few clinical trials of new drugs for in-
duction and maintenance therapy in EGPA due to its diverse 
and heterogeneous clinical features.4,16 
Although there is no consensus on the strategies for select-
ing therapeutic regimens for induction and maintenance ther-
apies for EGPA, a five-factor score (FFS), that was proposed by 
the French Vasculitis Study Group, has been used as a standard 
for the selection of therapeutic drugs.17 In the multivariable 
analysis of various clinical manifestations, age >65 years [haz-
ard ratio (HR) 3.3], renal insufficiency (creatinine ≥150 μmol/L, 
HR 1.5), gastrointestinal signs (HR 1.5), cardiac insufficiency 
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(HR 1.5), and ear, nose, and throat (ENT) manifestations (HR 
0.5) were significantly associated with 5-year mortality. Accord-
ingly, FFS consists of these five items, and a score of 1 is assigned 
to each item of age >65 years, renal insufficiency (creatinine 
≥150 μmol/L), gastrointestinal signs, cardiac insufficiency and 
no ENT manifestations. The 5-year mortality rates in patients 
with FFS=0 and FFS=1 were assessed at 9% and 21%, respec-
tively, whereas it was significantly elevated up to 40% in those 
with a FFS of 2 or greater.18 Thus, the therapeutic strategy for 
EGPA is now being made based on FFS=0 or FFS>1. In non-se-
vere EGPA patients, glucocorticoid has been recommended 
as both induction and maintenance therapies.17,19 Azathioprine 
might be considered effective as a maintenance therapeutic regi-
men for EGPA, like MPA and GPA. However, a recent study re-
ported that adding azathioprine to induction therapy with glu-
cocorticoid did not increase remission rates, diminish relapse 
risk, or spare the dose of glucocorticoid in non-severe EGPA pa-
tients. The initial remission rate was assessed as 100% for aza-
thioprine and 96.2% for placebo. Furthermore, a combination 
of glucocorticoid with azathioprine did not reduce the exacer-
bation rates of EGPA-related asthma and rhinosinusitis.20 Thus, 
in patients with FFS=0, a monotherapy of glucocorticoid is cur-
rently recommended in both induction and maintenance ther-
apy, whereas in severe EGPA patients with FFS >1, a combina-
tion of cyclophosphamide with glucocorticoid has been widely 
used as the first-line induction therapeutic regimen, with aza-
thioprine as the maintenance therapeutic regimen.21 
In patients with EGPA refractory to a combination induction 
therapy of cyclophosphamide and glucocorticoid, particularly 
in EGPA patients at a vasculitic stage, rituximab may be recom-
mended in MPA and GPA.17 In general, EGPA has been classi-
cally considered a Th2-mediated autoimmune disease.22 Up-
regulated production of Th-2 cell-associated cytokines such as 
interleukin (IL)-4, IL-5, and IL-13, were demonstrated in pe-
ripheral T cells from active EGPA patients.23,24 In contrast, in late 
EGPA patients at a vasculitic stage, the alteration of T cell pop-
ulations occurs from Th2 cells to Th1 and Th17 cells and further-
more, an increased concentration of IL-17A was confirmed in 
late EGPA patients.25 Therefore, it can be reasonably assumed 
that the use of rituximab in late EGPA patients may be as effec-
tive as in MPA and GPA patients.
There are currently two ongoing clinical trials of the efficacy 
of rituximab in EGPA patients. The first ongoing clinical trial is 
the rituximab in eosinophilic granulomatosis with polyangi-
itis (REOVAS) trial (phase III, comparative, multicentre, ran-
domised, controlled, double-blind and superiority research).26 
The REOVAS trial has four arms, including rituximab with FFS= 
0, conventional therapy with FFS=0, rituximab with FFS≥1, and 
conventional therapy with FFS≥1, and seeks to compare its po-
tential in induction therapy for EGPA (NCT 02807103). Another 
ongoing clinical trial (NCT 03164473) is seeking to compare 
the efficacy of rituximab with azathioprine as a maintenance 
therapeutic regimen for EGPA.26 Rituximab has occasionally 
been tried for induction therapy in a few cases of EGPA refrac-
tory to cyclophosphamide and glucocorticoid in Korea despite 
no official published case reports. However, the use of ritux-
imab has not been approved in Korea until now, and thus it is 
not covered by Korean National Health Insurance Service. We 
expect that based on positive results of currently conducted 
clinical trials on rituximab, the use of rituximab will be ap-
proved for use in EGPA patients in Korea soon. 
IL-5 regulates the proliferation, maturation, and differentia-
tion of eosinophils, and it plays a crucial role in the develop-
ment and progression of EGPA.27,28 Therefore, inhibiting IL-5- 
mediated signals may theoretically improve clinical symptoms 
of EGPA. Mepolizumab is an anti-IL-5 monoclonal antibody 
that binds to IL-5 and blocks the interaction between IL-5 and 
IL-5 receptor on the eosinophil surface.29 Pilot studies have 
demonstrated that mepolizumab is effective in the treatment 
of EGPA.30,31 Recently, the results of phase III randomized, pla-
cebo-controlled, double-blind, parallel-group clinical trial in-
vestigating the efficacy and safety of mepolizumab in relapsing 
or refractory EGPA have been reported. Mepolizumab (300 mg 
subcutaneous every 4 weeks) versus placebo, based on gluco-
corticoid with/without immunosuppressive therapy, had been 
administered to 68 participants for each group for 52 weeks. 
The two primary endpoints were the accrued weeks of remis-
sion during the study period and the proportion of participants 
in remission at weeks 36 and 48. Mepolizumab showed signif-
icantly more accrued weeks of remission than placebo (28% vs. 
3% of the participants having ≥24 weeks of accrued remission 
[odds ratio (OR) 5.9] and a higher proportion of participants 
in remission at week 36 and 48 [32% vs. 3% (OR 16.7)]. Remis-
sion occurred in 53% of the participants in the mepolizumab 
group, whereas it occurred in only 19% of those in the placebo 
group. The time to first relapse over the 52-week period was 
significantly longer in participants with mepolizumab than in 
those with placebo. The annualized relapse rate was 1.14 in the 
mepolizumab group, compared to 2.27 in the placebo group 
(rate ratio 0.50). In addition, mepolizumab reduced the pro-
portion of participants who had an average daily dose of pred-
nisolone or prednisone of 4.0 mg or less per day during weeks 
48 through 52 (OR 0.20). There were several limitations such 
as various doses of glucocorticoid or difficulty in observing the 
effect of mepolizumab on inflammatory markers due to glu-
cocorticoid at entry and no standard assessment tool for EGPA. 
However, this trial contributed to the extended approval of the 
use of mepolizumab to treat adult patients with EGPA by the 
United States Food and Drug Administration.32 In addition to 
mepolizumab, reslizumab (a monoclonal antibody against IL-
5) and benralizumab (a monoclonal antibody against IL-5 re-
ceptor α) are being evaluated through clinical trials (NCT 
02947945 and NCT 03010436).26 Mepolizumab is only ap-
proved by the Korean Food and Drug Administration for severe 
asthma. In the near future, we expect that mepolizumab will 
be approved by the Korean Food and Drug Administration 
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and may be a solution for refractory EGPA.
PREDICTIVE FACTORS FOR PROGNOSIS 
IN KOREAN PATIENTS WITH EGPA 
A previous study investigated independent predictive factors 
for the prognosis of EGPA in Korean patients in 2013. They 
retrospectively reviewed the medical records of 52 Korean pa-
tients with EGPA. The most common organ affected by EGPA 
was the respiratory tract, followed by nerves. Clinical remis-
sion was achieved in 95.3% of patients, among whom 16.3% 
experienced relapse. Remission for more than 6 months was 
more often observed in patients with older age, diagnosis in an 
earlier stage, pulmonary manifestations, generalized symptoms, 
and high C-reactive protein than those without.33 We included 
30 Korean patients with EGPA and investigated the initial pre-
dictors at diagnosis of relapse during follow-up. Respiratory 
symptoms were common clinical manifestations, such as asth-
ma (86.7%) and lung parenchymal involvement (76.7%). The 
mean FFS was 0.9, and a FFS of 1.0 was calculated as a cut-off 
to predict relapse of EGPA by a receiver operator characteristic 
curve. Finally, we demonstrated that relapse was more frequent 
in patients with FFS ≥1 than those with FFS <1 (68.8% vs. 7.1%, 
relative risk 28.6).34
COMPARISON BETWEEN ANCA-POSITIVE 
VERSUS ANCA-NEGATIVE EGPA 
Cottin, et al.35 retrospectively reviewed the medical records of 
157 EGPA patients. They divided all patients into two groups 
based on the presence of ANCA and compared clinical and 
laboratory variables between the two groups. ANCA-positive 
EGPA patients more frequently exhibited weight loss, myalgia, 
and arthralgia than ANCA-negative EGPA patients. Also, AN-
CA-positive EGPA patients exhibited increased frequencies of 
definitive vasculitis, biopsy-proven necrotising vasculitis, necro-
tising glomerulonephritis or crescentic glomerulonephritis, 
haematuria, and leukocytoclastic capillaritis and/or eosino-
philic infiltration of the arterial walls, compared to ANCA-nega-
tive EGPA patients. In addition, mononeuritis multiplex, myo-
carditis and renal disease were more often observed in ANCA-
positive EGPA patients than those without ANCA. Sokolowska, 
et al.36 also compared clinical features between 15 ANCA-pos-
itive and 3 ANCA-negative EGPA patients. At the time of diag-
nosis, ANCA-positive EGPA patients showed a higher rate of 
renal, cutaneous, and peripheral nervous manifestations than 
ANCA negative patients. However, ANCA positivity was not 
proven to affect the frequency of relapse. 
In terms of Korean patients with EGPA, Kim, et al.33 compared 
clinical features between ANCA-positive and negative patients. 
ANCA-positive EGPA patients showed a higher frequency of 
renal involvement than ANCA-negative EGPA patients. Mean-
while, we subdivided EGPA patients into MPO-ANCA-positive, 
PR3-ANCA-positive and ANCA-negative EGPA groups, and 
compared clinical features among them. A total of 36.7% of 
patients had MPO-ANCA and 10.0% had PR3-ANCA. Among 
clinical manifestations, MPO-ANCA-positive patients with 
EGPA exhibited a higher frequency of cutaneous manifesta-
tions than PR3-ANCA-positive and ANCA-negative patients 
(72.7% vs. 0% and 72.7% vs. 31.3%, respectively). Proteinuria 
(>1 g/day) was significantly more often observed in both MPO-
ANCA-positive and PR3-ANCA-positive patients than in ANCA-
negative patients (27.3% vs. 6.3% and 66.7% vs. 6.3%, respec-
tively). In addition, MPO-ANCA-positive patients with EGPA 
showed a higher relapse rate than ANCA-negative patients with 
EGPA (54.6% vs. 25.0%).34 Taking the results of the two previous 
studies together, in Korean patients with EGPA, ANCA posi-
tivity may be associated with skin and renal involvement for 
EGPA at diagnosis and with the occurrence of relapse during 
follow-up. 
HYPEREOSINOPHILIC SYNDROME 
VERSUS EGPA 
In daily clinical practice, it is not easy to distinguish between 
hypereosinophilic syndrome (HES) and EGPA, because they 
share similar clinical features, such as eosinophilia in the pe-
ripheral blood, paranasal sinusitis, and acute or chronic eosin-
ophilic lung involvement.6,37,38 The currently used diagnostic 
criteria for HES are the refined definitions of HES, which were 
proposed in 2010 (the 2010 definition of HES). The 2010 defi-
nition of HES consists of two items: one is peripheral blood 
eosinophilia >1500/mm3 on at least two separate occasions or 
histological confirmation of tissue eosinophil infiltration as-
sociated with symptoms, and the other is exclusion of second-
ary aetiology of peripheral blood eosinophilia.37 Thus, hypere-
osinophilia is not obligatory in cases of evident eosinophil 
infiltration in damaged end organs. So far, asthma or asthmatic 
history has been considered as a clue favouring EGPA based 
on the 2010 definition of HES and the 1990 ACR criteria for 
EGPA,6,37 as asthma is one of the pre-existing aetiologies of hype-
reosinophilia. However, asthma can occur as end-organ dam-
age of HES.39 ANCA positivity can be definite evidence to dis-
tinguish EGPA from HES; however, the frequency of ANCA in 
EGPA has been reported as 40% approximately.17 Thus, in a ma-
jority of cases, ANCA is not a good parameter for distinguishing 
between HES and ANCA-negative EGPA. 
Meanwhile, HES is currently classified into six categories, 
such as myeloproliferative HES, lymphocytic HES, undefined 
HES, overlap HES, associated HES, and familial HES. The cat-
egory of associated HES, which is composed of significant pe-
ripheral eosinophilia under the conditions known to provoke 
eosinophilia, includes EGPA, systemic mastocytosis, inflam-
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matory bowel disease, sarcoidosis and human immunodefi-
ciency virus infection.40 Thus, because EGPA is included in the 
category of associated HES, and immunosuppressive drugs 
for allergic diseases, such as mepolizumab, are now approved 
for the treatment of EGPA, the boundary between the two dis-
eases is becoming gradually obscure. We are now conducting 
a retrospective study to investigate a new laboratory value 
with which to help to distinguish HES from EGPA in Korean 
established patients. We have tentatively concluded that initial 
white blood cell and eosinophil counts may be useful markers 
with which to differentiate between the two diseases (unpub-
lished). 
IMMUNOGLOBULIN G4 AND EGPA 
Humans express four subclasses of immunoglobulin (IgG), 
such as IgG1, IgG2, IgG3, and IgG4, and the proportion of 
IgG4 is at most approximately 5%.41 Since both IgG4 produc-
tion and early stage EGPA are primarily associated with the 
up-regulation of Th2 cytokines, enhanced serum IgG4 levels 
in patients with EGPA has been often reported.42 A previous 
study investigated whether serum IgG4 levels might be asso-
ciated with the disease activity or prognosis of EGPA. They in-
cluded 24 patients with active EGPA and 22 patients with in-
active EGPA. They also included 26 patients with GPA, 25 with 
atopic asthma, and 20 healthy people as controls. Serum IgG4 
levels were significantly increased in patients with active 
EGPA, compared to controls, and furthermore, they were well 
correlated with the extent of organ damage and disease activi-
ty.43 However, another previous longitudinal cohort study ob-
tained blood samples from 25 patients with EGPA (105 visits) 
and demonstrated that serum IgG4 levels and IgG4/IgG ratio 
did not significantly reflect the current activity of EGPA in es-
tablished patients.44 Therefore, the role of serum IgG4 level as a 
biomarker to predict the current activity of EGPA still remains 
elusive. 
Researchers have wondered whether elevated serum IgG4 
levels in EGPA result in IgG4-related disease (IgG4-RD). High 
serum IgG4 level is one of the comprehensive diagnostic cri-
teria for IgG4-RD: organ involvement, serum IgG4 level >135 
mg/dL and IgG4+/IgG+ cells >40% or IgG4+ cells/high power 
field >10 on tissues.45 A previous study determined the frequen-
cy of IgG4-RD and other disease in patients with elevated se-
rum IgG4 levels. Of 3300 patients, 158 (4.8%) patients showed 
elevated serum IgG4 levels (>140 mg/dL) and 29 of 158 patients 
(18.4%) were classified as definite and possible IgG4-RD.46 Ac-
cordingly, in approximately 20% of patients with elevated se-
rum IgG4 levels, IgG4-RD may occur. 
Nonetheless, there have been few studies reporting the con-
comitant occurrence of IgG4-RD in EGPA patients. A previous 
multicentre observational study included 13 patients who were 
diagnosed with AAV and IgG4-RD. Of 18 patients, 13 patients 
were concomitantly diagnosed with both diseases. Among 18 
patients, 14 patients were classified as GPA, 3 patients as MPA 
and only one patient as EGPA.47 We reviewed the medical re-
cords of 12 EGPA patients who had serum IgG4 levels and his-
tological results. The mean level of IgG4 was 1983.3 mg/dL and 
all EGPA patients exhibited serum IgG4 levels >135 mg/dL 
(min 151.1, max 5420.0). None of 12 EGPA patients satisfied 
comprehensive diagnostic criteria for IgG4-RD.45 Therefore, 
we conclude that IgG4-RD rarely occurs in EGPA patients de-
spite elevated serum IgG4 levels. We hypothesise that similar 
pathogenic mechanisms of EGPA and IgG4-RD may shift to-
wards only one disease entity rather than both diseases simul-
taneously. 
On the other hand, we wondered if IgG4-RD may be associ-
ated with AAV, excluding EGPA. We investigated whether ele-
vated serum IgG4 levels are associated with concurrent IgG4-
RD in Korean patients with MPA and GPA. Interestingly, 37% 
of MPA and GPA patients had elevated serum IgG4 levels at 
diagnosis. However, no patient with elevated serum IgG4 lev-
els was classified as IgG4-RD based on comprehensive diag-
nostic criteria for IgG4-RD. We also provided an assumption 
that the cross-sectional IgG4 levels might reflect activity and in-
flammatory burden of Korean patients with MPA and GPA.48 
Taken together with these results, while serum IgG4 levels may 
be elevated in EGPA patients, they do not seem to be associated 
with the concurrent occurrence of IgG4-RD. In addition, serum 
levels of IgG4 may reflect the cross-sectional activity of AAV. 
RESOLVED HEPATITIS B VIRUS IN EGPA
The prevalence of patients with resolved hepatitis B virus (HBV) 
infection, which refers to conditions of clearance of circulat-
ing hepatitis B surface antigen (HBsAg) and appearance of 
antibody to hepatitis B core antigen (anti-HBc) with or without 
antibody to HBsAg (anti-HBs) is approximately 60% in en-
demic areas, particularly in Korea.49 Therefore, patients with re-
solved HBV infection had been exposed to HBV and achieved 
an immune response to control viral replication. So far, HBV 
has been known to be associated with polyarteritis nodosa 
and recently a new category of HBV associated vasculitis was 
established in 2012.1,50 We previously reported that resolved 
HBV infection may influence vasculitis activity at diagnosis 
and subsequently relapse after remission in EGPA patients.51 We 
referred to a previous report on Churg-Strauss vasculitis after 
hepatitis B vaccination52 and assumed that resolved HBV in-
fection might act as HBV vaccination. Resolved HBV infection 
might trigger the deterioration of the immune system, and ini-
tiate insidious allergic features and clinical symptoms of EGPA 
with a considerable time gap. If EGPA occurs after HBV reacti-
vation, however, how do we classify this case? The satisfaction 
of four or more items of the 1990 ACR criteria for EGPA may 
assign this case as EGPA. However, given that antiviral agent 
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should be necessary to control reactivated HBV, we believe 
that classifying this case as HBV associated vasculitis may be 
safer to the patient.
CONCLUSION
A considerable number of clinical features and pathogenic 
mechanisms of EGPA, HES and IgG4-RD overlap in that they 
are regulated by Th2 cell-mediated immune response. More-
over, EGPA belongs to small vessel vasculitis related to ANCA 
including GPA and MPA. Therefore, it is clinically important 
to distinguish EGPA from other diseases due to their different 
therapeutic and preventive strategies. So far, there have been 
noticeable advancements and changes in the classification cri-
teria for GPA and MPA, although the 1990 ACR criteria for 
EGPA are still widely used due to their high sensitivity and speci-
ficity. In contrast with treatment strategies for GPA and MPA, 
those for EGPA have not keep pace. Recently, several clinical 
trials have demonstrated the efficacy of biological agents, such 
as rituximab and mepolizumab in EGPA patients. In the near fu-
ture, we expect to be able to better cope with the maintenance 
of remission and prevention of relapse for EGPA with the new 
drugs that are currently being evaluated in clinical trials. 
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